Ratio Therapeutics
Ratio Therapeutics seeks a Radiochemistry Scientist to advance proprietary TRILLIUM and MACROPA platforms in the development of targeted radioligand therapies for cancer. The role involves designing radiolabeling methods, optimizing small molecule targeting agents, and conducting quality control testing for preclinical studies. Success requires expertise in radioisotopes, chromatographic analysis, and a dedication to improving patient quality of life through innovative theranostic agents.
Headquarters
Boston, Massachusetts, United States
Company Size
11-50 employees
Founded
2021
Ratio Therapeutics is a discovery-to-early-clinical-stage biopharmaceutical company developing targeted radiopharmaceuticals for cancer patients. Its proprietary Trillium™ targeting scaffold combines pharmacokinetic modulation with advanced chelation to generate small-molecule targeting agents that selectively deliver therapeutic radioisotopes to tumors. The company advances candidates through preclinical and early clinical studies aiming to create best-in-class targeted radiotherapeutics with improved tumor targeting and safety. Ratio focuses on innovative chemistry and translational development to bring new radioligand therapies to patients.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Ratio Therapeutics.
4% below the average for this role
Scientist, Radiochemistry
Ferring
Sr. Associate Scientist, Radiochemistry
Bristol Myers Squibb
Sr. Associate Scientist, Radiochemistry
Bristol Myers Squibb
RayzeBio Scientist, Radiochemistry
Bristol Myers Squibb
Scientist/Sr. Scientist , CMC Radiochemistry (on-site in SSF)
Abdera Therapeutics
Scientist - Radiochemistry
AstraZeneca